Bending PDUFA’s Cost Curve: PhRMA Looking For Sustainable Program Growth
Industry feels that sufficient program management tools are in place, but a PDUFA VII negotiator says they need more time to mature.
You may also be interested in...
US FDA’s Top Two Vaccine Officials Announce Surprise Retirements
Departures of Marion Gruber and Philip Krause may stem from White House and CDC actions related to the COVID-19 vaccines.
US FDA Lowers FY '22 PDUFA Fees Due to Hiring, Attrition Concerns
The agency reissued the user fee notice, saying fewer dollars were needed for new staff.
US FDA Publishes, Then Withdraws, PDUFA Rates Because Process ‘May Not Be Well Understood’
User fees for FY 2021 were set to increase nearly 11%, but could have gone even higher; a new notice will be issued but timing is unclear.